Navigation Links
Tris Pharma Announces Approval of First-Ever Generic to Delsym® Dextromethorphan Polistirex Extended-Release Suspension
Date:5/31/2012

MONMOUTH JUNCTION, N.J., May 31, 2012 /PRNewswire/ -- Tris Pharma, a technology driven specialty pharmaceutical company, announced today that the US Food and Drug Administration (FDA) has approved the first-ever generic to Delsym®, an extended-release oral liquid suspension containing dextromethorphan polistirex.

Delsym was approved in 1982 and there has never been any generic alternative approved until now. Tris has pioneered the delivery of drugs in taste-neutral, extended release dosage forms such as liquids, ODT/chewable tablets, and strips that are otherwise associated with immediate release. Tris' versatile, patented technology avoids the use of toxic organic solvents by employing aqueous-based coating.

"This is the third extended-release liquid product approved by the FDA based on our patented technology, and speaks to Tris' capabilities to develop and commercialize difficult products," said Ketan Mehta, President & CEO of Tris Pharma.  "Leveraging our technology, Tris has built a robust and deep pipeline of unique products that will address many of today's unmet needs."

Perrigo is Tris' exclusive partner in distributing this product as a store-brand alternative to Delsym, and has announced that it will be shipping the product for the coming cough/cold/flu season.  Annual sales across the entire Delsym brand are estimated at more than $100 million.

Delsym is a registered trademark of Reckitt Benckiser, which is not associated with Tris Pharma or Tris' generic product.

About Tris Pharma

Tris Pharma is a specialty pharmaceutical company focused on the research and development of technologies driven products. Tris has pioneered the delivery of sustained release in the liquid, chewable/ODT and strip dosage forms so patients do not have to swallow a pill. Tris' Nobuse technology provides abuse deterrence for opioids and other abuse-prone drugs. Tris' R&D and manufacturing
'/>"/>

SOURCE Tris Pharma
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Taiho Pharmaceutical Announces Start of Global Phase III Clinical Trial in Metastatic Colorectal Cancer with Novel Antitumor Agent TAS-102
2. Lexicon Pharmaceuticals to present at the Jefferies 2012 Global Healthcare Conference
3. Perrigo Announces FDA Final Approval Of Tris Pharmas Dextromethorphan Polistirex Extended-Release Oral Suspension
4. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
5. Clean Room Environmental Best Practices for Medical Device & Pharmaceutical Manufacturers are Focus of Boston Seminar on June 6
6. AcelRx Pharmaceuticals Announces Pricing of a $10.0 Million PIPE Financing
7. Isis Pharmaceuticals to Present at the Goldman Sachs 33rd Annual Global Healthcare Conference
8. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
9. Cell Therapeutics Aequus BioPharma Validates its Proprietary GlycoPolymer Technology for the Extension of the Half-life of Therapeutic Protein Drugs
10. Faruqi & Faruqi, LLP Announces Investigation of ViroPharma Incorporated
11. Vanda Pharmaceuticals to Present at the Jefferies 2012 Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... Mass. , Sept. 17, 2014 /PRNewswire/ ... disease/ulcerative colitis (CD/UC) patients eligible for biologic ... receive a biologic. Surveyed gastroenterologists cite patients, ... reason for low penetration rates, followed by ... and UC patients receiving biologics, Janssen Biotech,s ...
(Date:9/17/2014)... MARINA DEL REY, Calif. , Sept. 17, ... launch of the Prostate Vanguard, an awareness campaign to ... replace multiple rectal needle biopsies of the prostate. ... of the prostate gland through the rectum. Multi-parametric MRI ... for diagnosing clinically-significant prostate cancer (CSPC). Men need ...
(Date:9/17/2014)... 2014 Bronstein, Gewirtz & Grossman, LLC is ... securities of PDL BioPharma, Inc. ("PDL BioPharma" or the ... are advised to contact Peretz Bronstein or ... info@bgandg.com or 212-697-6484. The investigation ... executives violated federal securities laws. On September ...
Breaking Medicine Technology:The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 2The Majority of Surveyed Gastroenterologists Agree that Biologics Should be Prescribed to More Patients in the Crohn's Disease and Ulcerative Colitis Treatment Paradigm 3Prostate Cancer Awareness Month - Stop Random Biopsies 2Prostate Cancer Awareness Month - Stop Random Biopsies 3Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Investigates claims on behalf of Investors of PDL BioPharma, Inc. --PDLI 2
... Janam Technologies LLC, a leading ... communicate wirelessly, today announced a new mobile healthcare ... product line with antimicrobial versions of the XM66 and ... provide the healthcare sector with rugged antimicrobial devices ...
... SILVER SPRING, Md., Oct. 14 The U.S. ... that their over-the-counter (OTC) chelation products are unapproved ... violation of federal law to make unproven claims ... chelation products. (Logo:   http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ...
Cached Medicine Technology:Janam Introduces Mobile Healthcare Product Line 2FDA Issues Warnings to Marketers of Unapproved 'Chelation' Products 2FDA Issues Warnings to Marketers of Unapproved 'Chelation' Products 3FDA Issues Warnings to Marketers of Unapproved 'Chelation' Products 4
(Date:9/17/2014)... Kathleen Doheny HealthDay Reporter ... major food and beverage companies have made good on their ... report finds. The companies, acting together through the Healthy ... the market between 2007 and 2012 and 1.5 trillion by ... "The 16 companies collectively met their pledge and exceeded their ...
(Date:9/17/2014)... at Moffitt Cancer Center, including Center Director Thomas A. Sellers, ... discovered 23 new regions of the genome that influence the ... Sept. 14 in Nature Genetics . , Prostate cancer ... 1 in 6 men will be diagnosed with the disease ... A man with one close relative, a brother or father ...
(Date:9/17/2014)... facial paralysis are perceived as being less happy simply ... facial expression, a new study from an Oregon State ... the important role the face plays in everyday communication ... with facial paralysis because of their disability, said Kathleen ... of Liberal Arts at Oregon State University. , "People ...
(Date:9/17/2014)... 2014 Tools4ever, the market ... solutions and Boston Software Systems, leader in ... relationship. Under the agreement, Tools4ever will ... functionality within its identity and password management ... healthcare automation platforms that streamline complex processes ...
(Date:9/17/2014)... Kessler Foundation is the recipient of one of ... Multiple Sclerosis (MS) Alliance. Nancy Chiaravalloti, PhD, ... Research, is principal investigator of the study, which ... in individuals with progressive multiple sclerosis. The Foundation ... the Alliance to investigators in nine countries, with ...
Breaking Medicine News(10 mins):Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 2Health News:Major U.S. Food Makers Cut 6.4 Trillion Calories From Products: Report 3Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 2Health News:Lack of facial expression leads to perceptions of unhappiness, new OSU research shows 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 2Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 3Health News:Tools4ever Partners with Boston Software Systems to Automate Identity and Password Management 4Health News:Kessler Foundation receives first-round grant from International Progressive Multiple Sclerosis Alliance 2
... Older workers benefit most from a modest health behavior ... personal coaching. University of Illinois at Chicago researchers ... interventions assessing older workers, health behaviors and outcomes. The ... an upcoming issue of the American Journal of Public ...
... April 14 (HealthDay News) -- Trying to make the best of ... cope with losing their jobs, a new United Kingdom study finds. ... with their job loss were able to see the event as ... volunteering and study. They also took a contemplative view of ...
... SEATTLE Everyone knows that eating a low-fat, low-calorie diet ... study led by researchers at Fred Hutchinson Cancer Research Center ... body fat, diet and exercise are most effective when done ... of this randomized trial, led by Anne McTiernan, M.D., Ph.D., ...
... 14, 2011 An enzyme essential for DNA replication and ... exploited as anti-cancer therapy, say researchers at The Scripps Research ... in the April 15, 2011 issue of the journal Cell, ... flap endonucleases, which are essential to the life of a ...
... of Alberta shows that for best results in stable patients ... is the key to the best outcomes. Study co-authors Mark ... Clark, researcher in the Faculty of Nursing, along with fellow ... Public Health, and Ian Paterson in the Faculty of Medicine ...
... During the winter of 2008�, a three-week armed conflict ... named "Operation Cast Lead" resulted in hundreds of rocket ... this time children and their families spent hours and ... Although the psychological effects of children,s health are ...
Cached Medicine News:Health News:Older workers benefit from high-tech, high-touch health promotion 2Health News:Good Attitude Critical When Coping With Layoff Trauma 2Health News:Study finds diet plus exercise is more effective for weight loss than either method alone 2Health News:Study finds diet plus exercise is more effective for weight loss than either method alone 3Health News:Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target 2Health News:Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target 3Health News:Study suggests enzyme crucial to DNA replication may provide potent anti-cancer drug target 4Health News:Heart needs work after heart attack: U of A Study challenges the notion that the heart must rest 2Health News:Teachers-based intervention provides stress resistance in war-exposed children 2
Tendril DX active-fixation leads allows for lower thresholds initially and during the lead maturation phase....
... The Guidant Flextend lead ... pace/sense lead with an ... extendable/retractable helix design offers ... for permanent implantation in ...
... The PY series leads are ... leads for stimulation of either the ... active fixation screw can be extended ... pin. The lead tip contains an ...
Used with permanent pacing leads....
Medicine Products: